Prostate Specific Antigen Features

CME Articles

PCA3: What Is Its Role in Prostate Cancer Screening?

Although several biomarkers show promise, PCA3 has garnered substantial attention following FDA approval and its role in the diagnosis of PCa will grow.

Latest Prostate Specific Antigen News

PSA Doubling Time Predicts Salvage Radiation Outcomes

PSA Doubling Time Predicts Salvage Radiation Outcomes

PSA doubling time of 6 months or less and seminal vesicle invasion were significant predictors of biochemical recurrence.

Urology Referrals for Elevated PSA Unchanged

Urology Referrals for Elevated PSA Unchanged

New study examined the effect of a U.S. Preventive Services Task Force 2012 recommendation against routine PSA screening.

Optimal PSA Threshold For Targeted Biopsy Identified

Optimal PSA Threshold For Targeted Biopsy Identified

Diagnostic usefulness of magnetic resonance imaging/ultrasound (MRI/US) fusion targeted prostate biopsy optimized in PSA level of 5.2 ng/mL or higher.

Rising PSA with Testosterone Gel Linked with Specific Factors

Rising PSA with Testosterone Gel Linked with Specific Factors

Greater PSA increases seen in older men and those with lower baseline testosterone.

Early Prostate Cancer Post-Operation PSA Values Useful

Early Prostate Cancer Post-Operation PSA Values Useful

PSA levels at day 30 found to predict biochemical relapse risk in men with positive surgical margins.

Good Prostate Cancer (PCa) Outcomes Possible Despite Salvage Radiation Failure

Good Prostate Cancer (PCa) Outcomes Possible Despite Salvage Radiation Failure

Men who had PSA relapse after receiving post-radical surgery salvage radiation therapy had a median overall survival of nearly 14 years.

Palpable Tumors Plus Low PSA May Up Prostate Cancer Death Risk

Palpable Tumors Plus Low PSA May Up Prostate Cancer Death Risk

New study highlights the importance of digital rectal examinations in PCa patients with normal-range PSA at diagnosis.

Lower PSA Predicts Favorable Salvage Radiotherapy Outcomes

Lower PSA Predicts Favorable Salvage Radiotherapy Outcomes

Reduced likelihood of biochemical recurrence of prostate cancer also linked to concomitant hormonal therapy and positive surgical margins.

New Findings May Explain PSA Bounce

New Findings May Explain PSA Bounce

Transient rises in PSA after radiotherapy may be due to late damage to healthy prostatic tissue, evidence suggests.

ADT May Be Safely Deferred After PSA Relapse

ADT May Be Safely Deferred After PSA Relapse

Immediate ADT found to offer little or no survival advantage to prostate cancer who experience biochemical recurrence.

Maximal Tumor Diameter Predicts PSA Failure Risk

Maximal Tumor Diameter Predicts PSA Failure Risk

This parameter can identify prostate cancer patients for whom adjuvant radiation therapy after radical prostatectomy may be of no benefit.

Post-Brachytherapy PSA Bounce Linked to Sexual Activity

Post-Brachytherapy PSA Bounce Linked to Sexual Activity

PSA bounce was associated with significantly higher scores on the International Index of Erectile Function-15 questionnaire.

Study: Low-Risk PCa Increasingly T1c

Study: Low-Risk PCa Increasingly T1c

Men diagnosed with low-risk prostate cancer today have lower PSA levels and tumor volume than men 15 years ago.

PSA Nadir in ADT Recipients: The Lower, The Better

PSA Nadir in ADT Recipients: The Lower, The Better

The nadir should be below 0.01 ng/mL because even levels of 0.01 to 0.2 ng/mL predict an increased risk of adverse outcomes.

CTCs Predict Survival in Men with Metastatic CRPC

CTCs Predict Survival in Men with Metastatic CRPC

Higher circulating tumor cell counts are associated with an increased risk of death.